A Randomized, 12-month, placebo-controlled, pivotal, cross-over study of migalastat in treatment naïve Fabry patients who have an amenable mutation and GI symptoms.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 13 Jul 2017

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Jul 2017 According to an Amicus Therapeutics media release, this additional Phase 3 study previously requested by the Agency to assess Gastrointestinal (GI) symptoms is no longer required prior to an NDA submission.
06 Dec 2016 New trial record
28 Nov 2016 According to an Amicus Therapeutics media release, company is working with FDA to finalize the protocol of this trial and plans to initiate enrollment in 2017, with data expected in 2019. This trial will generate additional data which will support regulatory approval of migalastat for Fabry disease in the USA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com